GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Pubmed ID: 32351687
Publication Date: 2020/04/25

Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.


The benefit of inducing cellular senescence as a tumor suppressive strategy remains questionable due to the senescence-associated secretory phenotype. Hence, studies and development of senolytic compounds that induce cell death in senescent cells have recently emerged. Senescent cells are hypothesized to exhibit different upregulated pro-survival/anti-apoptotic networks depending on the senescent inducers. This might limit the effect of a particular senolytic compound that targets rather only a specific pathway. Interestingly, cellular senescence in prostate cancer (PCa) cells can be induced by either androgen receptor (AR) agonists at supraphysiological androgen level (SAL) used in bipolar androgen therapy or by AR antagonists. This challenges to define ligand-specific senolytic compounds.

Here, we first induced cellular senescence by treating androgen-sensitive PCa LNCaP cells with either SAL or the AR antagonist Enzalutamide (ENZ). Subsequently, cells were incubated with the HSP90 inhibitor Ganetespib (GT), the Bcl-2 family inhibitor ABT263, or the Akt inhibitor MK2206 to analyze senolysis. GT and ABT263 are known senolytic compounds. We observed that GT exhibits senolytic activity specifically in SAL-pretreated PCa cells. Mechanistically, GT treatment results in reduction of AR, Akt, and phospho-S6 (p-S6) protein levels. Surprisingly, ABT263 lacks senolytic effect in both AR agonist- and antagonist-pretreated cells. ABT263 treatment does not affect AR, Akt, or S6 protein levels. Treatment with MK2206 does not reduce AR protein level and, as expected, potently inhibits Akt phosphorylation. However, ENZ-induced cellular senescent cells undergo apoptosis by MK2206, whereas SAL-treated cells are resistant. In line with this, we reveal that the pro-survival p-S6 level is higher in SAL-induced cellular senescent PCa cells compared to ENZ-treated cells. These data indicate a difference in the agonist- or antagonist-induced cellular senescence and suggest a novel role of MK2206 as a senolytic agent preferentially for AR antagonist-treated cells.

Taken together, our data suggest that both AR agonist and antagonist induce cellular senescence but differentially upregulate a pro-survival signaling which preferentially sensitize androgen-sensitive PCa LNCaP cells to a specific senolytic compound.
Authors: Pungsrinont Thanakorn , Sutter Malika Franziska , Ertingshausen Maren C C M , Lakshmana Gopinath , Kokal Miriam , Khan Amir Saeed , Baniahmad Aria ,

Reference:

  1. ncbi.nlm.nih.gov. [Last access 2020/04/25].

Related products :

Catalog number Product name Quantity
SL100489-LNCaP Transfection Reagents and Kits, GenJet™ DNA In Vitro Tranfection Reagent for LNCaP was pre_optimized for most efficiently transfecting LNCaP cells. 1 ml
940002 LNCaP prostate cancer cell line Flask or Vial
EIAAB30443 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,Aprin,As3,Pds5b,Rat,Rattus norvegicus,Sister chromatid cohesion protein PDS5 homolog B
EIAAB30441 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,Aprin,As3,Kiaa0979,Mouse,Mus musculus,Pds5b,Sister chromatid cohesion protein PDS5 homol
EIAAB30444 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,APRIN,AS3,Homo sapiens,Human,KIAA0979,PDS5B,Sister chromatid cohesion protein PDS5 homol